No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
Compugen Bolsters Cancer Therapy Portfolio With New Patent
Compugen Expands Its Intellectual Property Portfolio With New U.S. Patent Covering Triple Combination Use Of COM902 (Reduced FC Anti-TIGIT) With Anti-PD-1 And Anti-PVRIG Antibodies
Roche Anti-TIGIT Therapy Fails to Extend Survival in Late-stage Lung Cancer Trial
Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Truist Financial Maintains Compugen(CGEN.US) With Buy Rating
Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript Summary